Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
- Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with pandemic adjuvant system
- FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States
Tweets from GSK
-
GSK @GSK
We’re contributing to the global response to #COVID19 and supporting the development of candidate vaccines by providing our adjuvant technology to China-based Clover Biopharmaceuticals. Learn more: gsk.to/390Wv4k #coronavirus
about 1 day ago -
GSK @GSK
#DYK there are nearly 30 million Americans who suffer from #osteoarthritis? Go #BehindTheScience to see how we hope to help those suffering from this condition have greater control in managing their health and wellbeing: gsk.to/37Is7KR
about 4 days ago
-
GSK @GSK
Thanks to all our employees, around the world, who have raised £4 million for our partnership with @savechildrenuk. Together we’ve helped nearly 3 million children in 46 countries. Learn more: gsk.to/2LDdSkZ 👇#globalhealthhd
about 7 days ago
